Pfizer: Fibromyalgia trials
The registry lists 12 Fibromyalgia studies with Pfizer as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 2Phase 2 4Phase 3 7No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With FibromyalgiaTerminatedNCT00696787Phase 2Results posted
- Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal WomenCompletedNCT00369343Phase 3Results posted
- A Study to Compare Two Ways of Completing Pain and Sleep Questions and to Evaluate a New Daily Questionaire for Assessing Fatigue in Fibromyalgia PatientsCompletedNCT00819624Not applicable
- Phase 1 Thorough QT (TQT) Study in Young Healthy VolunteersCompletedNCT00809289Phase 1
- Maintenance of Efficacy.WithdrawnNCT00796601Phase 3
- Open Label Extension Study of [S,S]-Reboxetine in Patients With FibromyalgiaTerminatedNCT00754221Phase 3
- A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.CompletedNCT00752505Phase 2
- A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.CompletedNCT00612170Phase 3
- Long-term OL Study of [S,S]-RBX in Patients With FibromyalgiaTerminatedNCT00607256Phase 3
- Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 PathwayCompletedNCT00456898Phase 1
- Study Evaluating DVS SR in Patients With Fibromyalgia SyndromeCompletedNCT00424892Phase 2/3
- Study Evaluating the Efficacy of DVS-233 in FibromyalgiaTerminatedNCT00301431Phase 2/3